Four Seasons Health Care collapsed after years of private equity investors rolling in one after another to buy its business, sell its real estate, and at times wrest multimillion-dollar profits from it through complex debt schemes. The deal-making failed to account for the true cost of senior care.
On top of fearing for their children’s lives, new parents of very fragile, very sick infants can face exorbitant hospital bills — even if they have insurance. Medical bills don’t go away if a child dies.
Two Missouri towns are without operating hospitals after private equity-backed Noble Health left both facilities mired in debt, lawsuits, and federal investigations. The hospitals’ new operator, Platinum Health, agreed to buy them in April for $2 and laid off the last employees in early September.
Texas is at least the 12th state to settle with St. Louis-based Centene Corp. over allegations that it overcharged Medicaid prescription drug programs.
In this episode, Julie Rovner, chief Washington correspondent for KHN, guides listeners through decades of dealings between Congress and Big Pharma.
Medicare and Medicaid pay “look-alike” health centers significantly more than hospitals for treating patients, and converting or creating clinics can help hospitals reduce their expenses.
A two-year congressional investigation has identified troubling lapses in the nation’s organ transplant system. Blood types mismatched, diseased organs transplanted anyway, and — most often — organs lost or damaged before they can save a life.
A nonprofit that trains people to apply for charity care has started teaching others how to negotiate with hospitals and debt collectors to lower the amount they owe.
Nonprofit RIP Medical Debt buys up unpaid hospital bills plaguing low-income patients and frees them from having to pay.
Under the Medicare drug negotiations provisions in the reconciliation bill, the federal government would see its outlays reduced by about $300 billion. That reduction wouldn’t result from cuts in benefits. Instead, Medicare would be empowered to leverage its market power to pay lower prices for certain drugs.
